Eisai said on March 1 that its board of directors approved the appointment of Hajime Shimizu, representative corporate officer in charge of subsidiaries, as president of EA Pharma to be established in April.EA Pharma will be created through the integration…
To read the full story
Related Article
- EA Pharma President Shimizu Dies at 59
February 20, 2017
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
BUSINESS
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





